The Pentagon has blown its eighth audit in a row, still unable to pass a full financial check of its books. The Department of War admitted in a fresh report thatThe Pentagon has blown its eighth audit in a row, still unable to pass a full financial check of its books. The Department of War admitted in a fresh report that

Pentagon audit failure streak hits eight years with $4.73T in liabilities outweighing assets

2025/12/20 08:41
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

The Pentagon has blown its eighth audit in a row, still unable to pass a full financial check of its books.

The Department of War admitted in a fresh report that it’s once again failed to account for what it owns versus what it owes, leaving $4.73 trillion in liabilities towering over its assets. The Pentagon also reiterated that it has pushed its clean audit goal to 2028, when Trump would’ve already been out of office.

The largest audit flagged 26 material weaknesses and 2 major deficiencies across financial reporting controls for fiscal year 2025.

A material weakness, in government terms, is a giant red flag; proof that errors and misstatements probably won’t be caught in time. And they had 26 of them, meaning there’s no real grip on the Pentagon’s accounting structure.

F-35 inventory records not reported

The F-35 Joint Strike Fighter program, the Pentagon’s most expensive weapon system, added fuel to the fire.

According to the report, the Department failed to include the program’s global spares pool in its financial records. That’s a huge pile of parts, gear, and equipment that nobody properly logged.

“Because the DoD is unable to provide or obtain accurate and reliable data to verify the existence, completeness, or value of its Global Spares Pool assets for the Joint Strike Fighter Program, we could not quantify the material misstatement in the DoD’s assets on the Agency-Wide Financial Statements,” the audit document stated.

Basically, they don’t know how much of the F-35 stockpile even exists, and even if it does, what it’s worth.

Defense Secretary Pete Hegseth responded to the report, saying the Pentagon “remains steadfast in its commitment to rigorous annual financial statement audits.” He added that the 2025 audit did show “significant progress,” but the department still has major clean-up to do.

The only wins this year? One material weakness was resolved and another one got merged into a broader category. Not a huge turnaround by any means.

Jules Hurst, acting comptroller, admitted the department won’t get a clean audit without speeding things up fast. “While we made significant progress in FY 2025, the Department of War will not reach its goal of achieving a clean financial statement audit without a significant acceleration of its efforts,” Hurst wrote in a letter included in the audit. “We will change the trajectory in FY 2026 to rapidly address longstanding issues through a revised strategy and approach.”

He added, “The Department of War is committed to resolving its critical issues and achieving an unmodified audit opinion by 2028.”

On the same day the audit dropped, the Senate confirmed Michael Powers as the Pentagon’s new comptroller. During his July confirmation hearing, Powers said his team would get to work “within weeks” to figure out clear milestones toward a clean audit, as required under the FY24 National Defense Authorization Act.

“The work is underneath: How do we get to a common or a couple of common financial systems,” Powers told lawmakers at the time.

All that’s left now is four more audit seasons and trillions of dollars to track.

Get $50 free to trade crypto when you sign up to Bybit now

Market Opportunity
4 Logo
4 Price(4)
$0.008073
$0.008073$0.008073
-1.36%
USD
4 (4) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09